Table 4b. Mean (s.d.) pharmacokinetic parameters of gemcitabine, dFdU and dFdCTP with or without tipifarnib (100–300 mg).

Variable	Units	Gem/cis (s.d.) n=23	Gem/cis+tipifarnib (s.d.) n=29	P-valuea
Plasma gemcitabine
Median tmax	Hours	0.50	0.50	—
Cmaxb	μg ml−1	12.5 (3.53)	12.6 (2.31)	0.197c
AUC0–48b	h μg ml−1	6.71 (2.12)d	6.67 (1.07)e	0.200f
t1/2	Hours	0.18 (0.06)d	0.55 (1.77)g	—
Plasma dFdU
Median tmax	Hours	0.6g	0.61h	—
Cmaxb	μg ml−1	25.6 (5.47)g	27.0 (4.89)h	0.028g
AUC0–48b	h μg ml−1	237 (89.4)d	274 (119)e	0.032f
t1/2	Hours	32.4 (26.2)g	10.2 (6.37)h	—
Mononuclear blood cell dFdCTP
AUC0–24b	h nanomol mg protein−1	18.3 (40.9)i	14.7 (22.9)j	0.303d

^aTwo-sided P-value for testing a difference between the two treatments. Only data from patients who completed the study were included.

^bParameter values adjusted to 750 mg m⁻² dose of gemcitabine.

^cn=22.

^dn=19.

^en=20.

^fn=14.

^gn=24.

^hn=30.

ⁱn=21.

^jn=26.

Gem=gemcitabine; cis=cisplatin.